Last reviewed · How we verify
NCT06277661
The Mom and Infant Outcomes (MOMI) Study
NA trial testing MOMI PODS in Postpartum Depression in 384 participants. Currently enrolling.
1 November 2027
Quick facts
| Lead sponsor | Ohio State University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 384 |
| Start date | 27 June 2024 |
| Primary completion | 1 November 2027 |
| Estimated completion | 1 March 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- MOMI PODS
- Enhanced Usual Care (EUC)
Conditions studied
- Postpartum Depression — all drugs for Postpartum Depression →
- Postpartum Anxiety — all drugs for Postpartum Anxiety →
- Cardiometabolic Syndrome — all drugs for Cardiometabolic Syndrome →
Sponsor
Ohio State University
Who can join
Eligibility, female only, with Postpartum Depression or Postpartum Anxiety. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigator's long-term goal is to mitigate pregnancy-related mortality (PRM) risk by systematically delivering scalable integrated clinical and supportive care that is effective for all. The investigator's central hypothesis is that the Multi-modal Maternal Infant Perinatal Outpatient Delivery System (MOMI PODS) will mitigate postpartum (PP) risk for all by increasing patient engagement with evidence-based cilnical and supportive care, thus improving biopsychosocial profiles that drive clinical risk. To test this hypothesis, the investigators will conduct a hybrid type 1 randomized controlled trial (RCT) of MOMI PODS versus enhanced usual care (EUC, which we will term MOMI CARE) among a total sample of up to 384 mother-infant dyads (192/group) following pregnancy affected by a cardiometabolic and/or mental health condition. The investigators will enroll participants during late pregnancy and collect data at baseline and 6 months and 1 year PP. The investigators will collect implementation and service data across sites.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06277661
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Postpartum Depression
Currently open trials in the same condition.
- NCT07398469 — A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone · recruiting
- NCT06442774 — MamaConecta: Digital Tool for Maternal Mental Health · NA · recruiting
- NCT06545760 — Admission to Kangaroo Mother Care (KMC) Ward and Maternal Postpartum Depression · NA · recruiting
- NCT05763537 — Understanding the Role of Doulas in Supporting People With PMADs · NA · recruiting
- NCT06462638 — COntact RElationship in Neonatal Intensive Care Unit · recruiting
Other Ohio State University trials
Trials by the same sponsor.
- NCT06542458 — Under-Represented Communities Diagnosed With SCD or MCI Through Tele-Cog · not yet recruiting
- NCT07217548 — Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients · NA · enrolling by invitation
- NCT07215221 — Implementation of TBI-RECOVER in Substance Use Treatment · NA · not yet recruiting
- NCT07278427 — Reducing Parental Substance Use and Enhancing Family Resilience Among Rural Families Through Ohio START · recruiting
- NCT07490444 — Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06277661 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ohio State University
- Last refreshed: 13 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06277661.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing